Detalhe da pesquisa
1.
P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position.
Bioorg Med Chem Lett
; 21(5): 1532-5, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21295466
2.
Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors.
Bioorg Med Chem Lett
; 21(5): 1536-40, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21295467
3.
Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
Bioorg Med Chem Lett
; 18(6): 2062-6, 2008 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18291642
4.
9-hydroxyazafluorenes and their use in thrombin inhibitors.
J Med Chem
; 48(7): 2282-93, 2005 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-15801822
5.
Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors.
J Med Chem
; 47(12): 2995-3008, 2004 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-15163182
6.
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.
J Med Chem
; 46(4): 461-73, 2003 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-12570369
7.
Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 1: Weakly basic azoles.
Bioorg Med Chem Lett
; 16(2): 338-42, 2006 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16257203
8.
Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.
Bioorg Med Chem
; 14(20): 6900-16, 2006 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16870455
9.
Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.
Bioorg Med Chem Lett
; 15(20): 4411-6, 2005 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16137886
10.
P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold.
Bioorg Med Chem Lett
; 15(11): 2771-5, 2005 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-15911253
11.
Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'.
Bioorg Med Chem Lett
; 13(2): 161-4, 2003 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-12482415
12.
3-amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors.
Bioorg Med Chem Lett
; 13(8): 1441-4, 2003 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-12668008
13.
Design and synthesis of potent and selective macrocyclic thrombin inhibitors.
Bioorg Med Chem Lett
; 13(16): 2781-4, 2003 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-12873514
14.
Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability.
Bioorg Med Chem Lett
; 14(16): 4161-4, 2004 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-15261262
15.
Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors.
Bioorg Med Chem Lett
; 13(5): 795-8, 2003 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-12617893
16.
Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position.
Bioorg Med Chem Lett
; 13(20): 3477-82, 2003 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-14505652
17.
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.
Bioorg Med Chem Lett
; 13(7): 1353-7, 2003 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-12657281